Free sign-up Sign in
Free sign-up Sign in
GlobalData

< View all reports

Biosimilars in Oncology

Recent trends in drug development have seen new medicines increase in price, and there is strong need for cheaper medicines in order to achieve global sustainable healthcare.

Biological drugs are some of the most expensive medicines to develop as they are large and complex. Biosimilar are alike approved biologic drugs, with no clinically relevant differences, and aim to achieve the same results at a lower price than their originator molecules.

This report will allow you to access invaluable data on the biosimilars market.

Doctor
  • Why should you buy this report?
  • Develop and design your in-licensing and out-licensing strategies by analysing the oncology biosimilar landscape
  • Gain an understanding of market potential and current regulatory outlook shaping the oncology biosimilars landscape in key markets
  • Learn about expert and high prescriber perceptions of biosimilars in the pharma industry

In oncology, biosimilar versions of six biologic drugs are available. The EMA has pioneered regulatory acceptance of biosimilars, and approved more biosimilars than the FDA. Beyond the major markets of the US and 5EU (France, Germany, Italy, Spain and UK), two emerging markets are key in the oncology biosimilars space: India, with the most approved biosimilars worldwide, and South Korea, which is home to major biosimilar developer Celltrion.

GlobalData’s Biosimilar market report takes a deep dive into the oncology biosimilars landscape in the 9 major markets, including an analysis of market potential, current and anticipated use of biosimilars, clinical and commercial concepts, important indications, and an overview of both leading and emerging developers. GlobalData anticipates that biosimilars will represent an important subset of this biologic-centered pharmaceutical market in years to come.

 

Purchase Today

Single user $ 7,995

Buy Now

reportstore@globaldata.com

+44 (0) 161 359 5813

Not ready to buy yet? Download our free report series guide on the Biosimilars Market

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.